CP-690,550 (tofacitinib)

DRUG2 trials

Sponsors

Pfizer

Conditions

Juvenile Idiopathic ArthritisRheumatoid Arthritis

Phase 1

Co-Administration Of Methotrexate And CP-690,550

CompletedNCT01745055

PfizerRheumatoid Arthritis

Start: 2005-04-30End: 2006-06-30Updated: 2013-02-04

Phase 3

Efficacy Study Of Tofacitinib In Pediatric JIA Population

CompletedNCT02592434

PfizerJuvenile Idiopathic Arthritis

Start: 2016-06-10End: 2019-05-16Updated: 2020-04-13

Related Papers

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial.

2025-10-31

Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial.

2025-10-01

Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial

The Journal of Rheumatology2025-05-011 citations

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.

2024-10-2110 citations

Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis

Arthritis Care & Research2024-08-131 citations

Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis

CPT Pharmacometrics & Systems Pharmacology2024-01-316 citations

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.

2021-11-09123 citations

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.

2017-12-2855 citations